Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MTNB 
Matinas BioPharma Holdings Inc (MTNB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: MTNB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46.82% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.39M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 2 | Beta 1.32 | 52 Weeks Range 0.47 - 7.21 | Updated Date 08/15/2025 |
52 Weeks Range 0.47 - 7.21 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -64.02% | Return on Equity (TTM) -192.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4183525 | Price to Sales(TTM) 46.5 |
Enterprise Value 4183525 | Price to Sales(TTM) 46.5 | ||
Enterprise Value to Revenue 37.2 | Enterprise Value to EBITDA -1.79 | Shares Outstanding 5086980 | Shares Floating 4712583 |
Shares Outstanding 5086980 | Shares Floating 4712583 | ||
Percent Insiders 12.31 | Percent Institutions 6.74 |
Upturn AI SWOT
Matinas BioPharma Holdings Inc
Company Overview
History and Background
Matinas BioPharma Holdings Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of infectious diseases and other serious conditions. It was founded in 2013. A significant milestone is the development and use of Lipid Nano-Crystal (LNC) platform technology.
Core Business Areas
- LNC Platform Technology: Matinas BioPharma's core is its Lipid Nano-Crystal (LNC) platform, used to encapsulate and deliver drugs more effectively. The LNC platform enhances drug delivery, reduces toxicity, and improves bioavailability.
- Lead Product Candidates: Developing product candidates like MAT2203, an oral formulation of amphotericin B, and MAT2501, an oral formulation of amikacin. These target serious fungal and bacterial infections.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. Jerome D. Jabbour serves as CEO. The organizational structure includes departments for research and development, clinical operations, and commercial strategy.
Top Products and Market Share
Key Offerings
- MAT2203: An oral formulation of amphotericin B designed to treat invasive fungal infections. It is currently in clinical development. Market share is not yet applicable as it is not yet approved. Competitors include intravenous amphotericin B formulations and other antifungal drugs from companies like Pfizer (PFE) and Merck (MRK).
- MAT2501: An oral formulation of amikacin, targeting multidrug-resistant bacterial infections. Currently in clinical development. Market share is not yet applicable as it is not yet approved. Competitors include intravenous amikacin and other antibiotics from companies like Roche (ROG) and Novartis (NVS).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant demand for new and effective treatments for infectious diseases. The market for antifungals and antibiotics is substantial and growing due to increasing resistance to existing drugs.
Positioning
Matinas BioPharma positions itself as a leader in oral drug delivery using its LNC platform. Its competitive advantage lies in the potential for improved efficacy, safety, and patient compliance compared to traditional intravenous formulations.
Total Addressable Market (TAM)
The total addressable market for antifungal and antibacterial drugs is estimated to be billions of dollars annually. Matinas BioPharma aims to capture a significant share of this market with its novel oral formulations, potentially exceeding $1 billion in revenue if successful.
Upturn SWOT Analysis
Strengths
- Novel LNC platform technology
- Potential for improved drug delivery and efficacy
- Oral formulations for convenience and patient compliance
- Experienced management team
Weaknesses
- Reliance on successful clinical trials
- Limited commercialized products
- Need for additional funding
- High regulatory hurdles
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Development of new LNC-based products
- Addressing unmet medical needs in infectious diseases
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Regulatory setbacks
- Patent challenges
Competitors and Market Share
Key Competitors
- PFE
- MRK
- GILD
- ABBV
- NVS
Competitive Landscape
Matinas BioPharma competes with established pharmaceutical companies that have greater resources and commercial infrastructure. Its advantage lies in its innovative LNC platform and oral drug delivery approach, which could offer improved patient outcomes.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by progress in clinical trials and partnerships.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its products. Analyst projections are based on these factors.
Recent Initiatives: Recent initiatives include advancing clinical trials for MAT2203 and MAT2501, seeking partnerships, and exploring new applications of the LNC platform.
Summary
Matinas BioPharma is a clinical-stage biopharmaceutical company with a promising LNC platform for oral drug delivery. Its success hinges on positive clinical trial results for MAT2203 and MAT2501. The company needs to secure partnerships and navigate regulatory hurdles to achieve commercial success. Competition from larger pharmaceutical companies poses a significant challenge, but the company's innovative technology offers a potential advantage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- Matinas BioPharma Website
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice and should not be used as the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Matinas BioPharma Holdings Inc
Exchange NYSE MKT | Headquaters Bedminster, NJ, United States | ||
IPO Launch date 2014-08-18 | Co-Founder, Chairman, CEO and President Mr. Jerome D. Jabbour J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.matinasbiopharma.com |
Full time employees 3 | Website https://www.matinasbiopharma.com | ||
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.